Themis Medicare Ltd
Themis Medicare Q1 FY27: Revenue ₹86.96 Cr, PAT ₹24.61 Cr
Q1 FY27 investor presentation: what the company reported on revenue, margins and projects.
Based on Themis Medicare Ltd's Q1 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
Q1 FY27 Net Revenue: ₹86.96 crore - Q1 FY26 Net Revenue: ₹97.58 crore - Year-on-Year (YoY) Revenue Change: -10.9% - Comment highlights headwinds in API business causing contraction in top line Q1 FY27 EBITDA: ₹(52.42) crore; Margin: (60.28)% - Q1 FY26 EBITDA: ₹(10.08) crore; Margin: (10.33)% - EBITDA Y-o-Y change: (420.0)% - Q1 FY27 PAT: ₹24.61 crore; Margin: 28.30% - Q1 FY26 PAT: ₹(14.22) crore; Margin: (14.57)% - PAT Y-o-Y change: 273.1% - Operating margin (EBITDA margin) contracted significantly due to headwinds in API business, price adjustments in inventory, and one-off expenses (page 8).
From Themis Medicare Ltd's Q1 FY27 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q1 FY27 Net Revenue: ₹86.96 crore
- Q1 FY26 Net Revenue: ₹97.58 crore
- Year-on-Year (YoY) Revenue Change: -10.9%
- Comment highlights headwinds in API business causing contraction in top line
- Management Comment (Page 5): Focus on strengthening profitability and sustainable growth, with optimism on improving business momentum supported by operational efficiencies and gradual recovery in core segments
2 more points management made on revenue & sales performance
Profitability & Margins
See what Themis Medicare Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Themis Medicare Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Themis Medicare Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹77 Cr, net profit ₹9 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Themis Medicare Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Natural Capsules Ltd (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
- Aptus Pharma Ltd (Q1 FY27)
Revenue from Operations for H2 FY26: ₹32.20 crore, up 117.5% YoY from ₹14.80 crore in H2 FY25 (Page 23) . Key concall takeaways from Aptus Pharma Ltd's Q1 FY27…
- RPG Life Sciences Ltd (Q1 FY27)
Q1 FY27 Revenue from Operations: ₹195.7 crores, up 15.8% YoY (Q1 FY26: ₹168.9 crores) [Page 18] . Key concall takeaways from RPG Life Sciences Ltd's Q1 FY27…
- SMS Pharmaceuticals Ltd (Q1 FY27)
Q1FY27 revenue from operations: ₹207 crore, up 6% YoY (Page 6, 5) . Key concall takeaways from SMS Pharmaceuticals Ltd's Q1 FY27 earnings call — and how it…
Frequently Asked Questions
What were Themis Medicare Ltd Q1 FY27 results?
Q1 FY27 Net Revenue: ₹86.96 crore - Q1 FY26 Net Revenue: ₹97.58 crore - Year-on-Year (YoY) Revenue Change: -10.9% - Comment highlights headwinds in API business causing contraction in top line Q1 FY27 EBITDA: ₹(52.42) crore; Margin: (60.28)% - Q1 FY26 EBITDA: ₹(10.08) crore; Margin: (10.33)% - EBITDA Y-o-Y change: (420.0)% - Q1 FY27 PAT: ₹24.61 crore; Margin: 28.30% - Q1 FY26 PAT: ₹(14.22) crore; Margin: (14.57)% - PAT Y-o-Y change: 273.1% - Operating margin (EBITDA margin) contracted significantly due to headwinds in API business, price adjustments in inventory, and one-off expenses (page 8).
What is Themis Medicare Ltd share price analysis?
Themis Medicare Ltd currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹1,142 Cr. Investors should review the full earnings analysis for detailed insights.
Is Themis Medicare Ltd planning capital expenditure?
The investor presentation mentions the following capex, capacity expansion, and projects: - Vertical Integration with state-of-the-art manufacturing facilities: - Formulations plant in Haridwar - Synthetic APIs plants in Hyderabad and Vapi - Capacities: - Formulations: 520 mn tablets, 9 mn ointment tubes, 36 mn ampoules, 12 mn vials, 6 mn pre-filled syringes p.a. - Synthetic APIs: Hyderabad - 120 MT; Vapi - 191 MT p.a. - R&D Investments: - Consistent investment around Rs.
Keep Themis Medicare Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.